The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
FGF-21 as a novel metabolic regulator
Open accessAbstract
Diabetes mellitus is a major health concern, affecting more than 5% of the population. Here we describe a potential novel therapeutic agent for this disease, FGF-21, which was discovered to be a potent regulator of glucose uptake in mouse 3T3-L1 and primary human adipocytes. FGF-21-transgenic mice were viable and resistant to diet-induced obesity. Therapeutic administration of FGF-21 reduced plasma glucose and triglycerides to near normal levels in both ob/ob and db/db mice. These effects persisted for at least 24 hours following the cessation of FGF-21 administration. Importantly, FGF-21 did not induce mitogenicity, hypoglycemia, or weight gain at any dose tested in diabetic or healthy animals or when overexpressed in transgenic mice. Thus, we conclude that FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In general, FGF21 stimulates the uptake of glucose by adipocytes and inhibits the production of glucose in the liver.”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“FGF21 acts in the control of glucose and lipid homeostasis (Kharitonenkov et al., 2005).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“In addition, FGF21 appears to protect pancreatic β cells from cell death induced by glycotoxicity (Kharitonenkov et al., 2005, 2007).”
From Physical Exercise-Induced Myokines and Muscle-Adipose Tissue Crosstalk: A Review of Current Knowledge and the Implications for Health and Metabolic Diseases (2018) · cites this paper as Kharitonenkov et al., 2005
Experimental — accuracy not yet measuredIn the citing paper
“Interestingly, mice that overexpress FGF-21, a circulating FGF which is induced by a ketogenic diet 106, are lean and have increased brown fat 107, suggesting that the beneficial metabolic effects induced by a ketogenic diet are brought about in part by increases in BAT mass.”
From Cellular bioenergetics as a target for obesity therapy (2010) · cites this paper as [107]
In the citing paper
“FGF21 binding promotes the formation of a dimeric FGFR1c–KLB signalling complex, which activates the intracellular tyrosine kinase domains of FGFR1c and propagates signalling through phosphorylation by the kinase ERK46,53,58,59”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“prolonged administration of FGF21 or FGF21 analogues has important metabolic effects, including a marked decrease in body weight in rodents and non-human primates, and more modest effects on body weight in humans3,40,58,77,78.”
From Metabolic messengers: FGF21 (2021) · cites this paper as [58]
In the citing paper
“overexpression of FGF21 is highly protective [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“activation of the FGF21/FGFR1c/KLB receptor complex results in the phosphorylation of ERK1/2 and FRS2α [135].”
From Hepatokines and metabolism: Deciphering communication from the liver (2021) · cites this paper as [135]
In the citing paper
“A myriad of studies ensued demonstrating that administering FGF21 to obese or diabetic rodents and primates markedly reduced body weight and significantly improved carbohydrate and lipid homeostasis (21, 64, 65, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In rodents, pharmacological levels of FGF21 increase energy expenditure (64, 141), which results in increased food intake (54, 64).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Since FGF21 administration increases energy expenditure and the browning of adipose tissues in vivo (21, 64, 141), it was hypothesized that FGF21 regulates adaptive thermogenesis in response to cold.”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“When administered to diabetic and obese animal models, FGF21 provides multiple metabolic benefits and has been shown to decrease blood glucose levels and body weight, improve insulin and leptin sensitivity, improve plasma lipid profiles, and decrease hepatic steatosis (21, 64, 141, 142).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“Importantly, in animal models FGF21 treatment not only prevents (64) but also reverses diabetes and obesity (21, 141).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“In addition, FGF21 enhances insulin sensitivity in primary brown adipocytes (86) but not in primary white adipocytes (64, 86).”
From Fibroblast Growth Factor 21: A Versatile Regulator of Metabolic Homeostasis (2018) · cites this paper as [64]
In the citing paper
“FGF21’s ability to reduce body weight, glucose levels, and lipid concentrations in models of obesity generated substantial initial interest”
From FGF21 and the physiological regulation of macronutrient preference (2020) · cites this paper as [114]
In the citing paper
“Fibroblast growth factor 21 (FGF21) was first identified as an hepatokine 61 and has been shown to be necessary for the adaptation to fasting 62, 63.”
From Inter‐organ communication: a gatekeeper for metabolic health (2019) · cites this paper as [61]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell Signaling by Receptor Tyrosine Kinases
Lemmon, M. A., & Schlessinger, J. (2010) · Cell · doi:10.1016/j.cell.2010.06.011 · Cited by 7,929
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Cell Signaling by Receptor Tyrosine Kinases
Schlessinger, J. (2000) · Cell · doi:10.1016/s0092-8674(00)00114-8 · Cited by 3,774
Ornitz, D. M., & Itoh, N. (2001) · Genome biology · doi:10.1186/gb-2001-2-3-reviews3005 · Cited by 1,985
Frederich, R. C., Hamann, A., Anderson, S., Löllmann, B., Lowell, B. B., & Flier, J. S. (1995) · Nature Medicine · doi:10.1038/nm1295-1311 · Cited by 1,660
Fibroblast growth factors, their receptors and signaling
Powers, C. J., McLeskey, S. W., & Wellstein, A. (2000) · Endocrine-related cancer · doi:10.1677/erc.0.0070165 · Cited by 1,332
Glucose Transporters and Insulin Action — Implications for Insulin Resistance and Diabetes Mellitus
Shepherd, P. R., & Kahn, B. B. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907223410406 · Cited by 1,295
SIGNALLING BY RECEPTOR TYROSINE KINASES
Fantl, W. J., Johnson, D. E., & Williams, L. T. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.62.1.453 · Cited by 1,118
Cheatham, B., Vlahos, C. J., Cheatham, L. A., Wang, L., Blenis, J., & Kahn, C. R. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4902-4911.1994 · Cited by 1,062
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,012
Research works printed but not linked: 3
- Konishi, 1999, J. Biol. Chem., 255, 12119
- Shah, 2000, J. Clin. Endocrinol. Metab., 85, 4053
- Cheatham, 1994, Mol. Cell. Biol., 14, 4902, 10.1128/MCB.14.7.4902 · DOI
Cited by
Sorted by citations
Items 901–1,000 of 1,008
Genetic models of PGC-1 and glucose metabolism and homeostasis
Rowe, G. C., & Arany, Z. P. (2013) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-013-9273-5 · Cited by 38
Li, K., Li, L., Yang, M., Zong, H., Liu, H., & Yang, G. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0335 · Cited by 36
Elevated Serum Fibroblast Growth Factor 21 in Humans with Acute Pancreatitis
Shenoy, V. K., Beaver, K. M., Fisher, F. M., Singhal, G., Dushay, J. R., Maratos–Flier, E., & Flier, S. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164351 · Cited by 36
Llanos, P., & Palomero, J. (2022) · Cells · doi:10.3390/cells11244008 · Cited by 39
FGF21, energy expenditure and weight loss – How much brown fat do you need?
Straub, L. G., & Wolfrum, C. (2015) · Molecular Metabolism · doi:10.1016/j.molmet.2015.06.008 · Cited by 35
Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients
Han, X., Chen, C., Cheng, G., Xie, C., Yang, M., Shou, X., & Sun, C. (2015) · Cytokine · doi:10.1016/j.cyto.2015.02.019 · Cited by 35
Leptin as a Potential Regulator of FGF21
Asrih, M., Veyrat‐Durebex, C., Poher, A.-L., Lyautey, J., Rohner‐Jeanrenaud, F., & Jornayvaz, F. R. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000443070 · Cited by 35
The Nuclear Receptor Rev-erbα Regulates Adipose Tissue-specific FGF21 Signaling
Jager, J., Wang, F., Fang, B., Lim, H., Peed, L. C., Steger, D. J., Won, K., Kharitonenkov, A., Adams, A. C., & Lazar, M. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.719120 · Cited by 35
Wu, H., Liu, Y., Chen, X., Zhu, D., Ma, J., Yan, Y., Si, M., Li, X., Sun, C., Yang, B., et al. (2017) · Pharmacology · doi:10.1159/000452492 · Cited by 35
Estradiol Regulation of Brown Adipose Tissue Thermogenesis
González‐García, I., Tena‐Sempere, M., & López, M. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-70178-3_15 · Cited by 35
Le, C. T., Nguyen, G., Park, S. Y., Choi, D. H., & Cho, E.-H. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192146 · Cited by 35
Dietary protein dilution limits dyslipidemia in obesity through FGF21-driven fatty acid clearance
Maida, A., Zota, A., Vegiopoulos, A., Appak‐Baskoy, S., Augustin, H. G., Heikenwälder, M. F., Herzig, S., & Rose, A. J. (2018) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2018.03.027 · Cited by 34
The anti-obesity effect of FGF19 does not require UCP1-dependent thermogenesis
Antonellis, P. J., Droz, B. A., Cosgrove, R., O’Farrell, L. S., Coşkun, T., Perfield, J. W., Bauer, S. M., Wade, M. R., Chouinard, T. E., Brozinick, J. T., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.006 · Cited by 37
Hong, E. S., Lim, C., Choi, H. Y., Lee, Y. K., Ku, E. J., Moon, J. H., Park, K. S., Jang, H. C., & Choi, S. H. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000776 · Cited by 35
Queen, N. J., Bates, R., Huang, W., Xiao, R., Appana, B., & Cao, L. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.011 · Cited by 38
Association of metabolic parameters and rs726344 in FNDC5 with serum irisin concentrations
Ebert, T., Kralisch, S., Wurst, U., Scholz, M. R., Stümvoll, M., Kovacs, P. L., Faßhauer, M., & Tönjes, A. (2015) · International Journal of Obesity · doi:10.1038/ijo.2015.157 · Cited by 35
Metabolic actions of FGF21: molecular mechanisms and therapeutic implications
Ge, X., Wang, Y., Lam, K. S., & Xu, A. (2012) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2012.06.011 · Cited by 35
Kotulák, T., Drápalová, J., Kopecky, P., Lacinová, Z., Kramar, P., Říha, H., Netuka, I., Malý, J., Housa, D., Bláha, J., et al. (2011) · Physiological Research · doi:10.33549/physiolres.932134 · Cited by 35
Glucagon receptor signaling regulates weight loss via central KLB receptor complexes
Nason, S. R., Antipenko, J., Presedo, N., Cunningham, S. E., Pierre, T. H., Kim, T., Paul, J. R., Holleman, C., Young, M. E., Gamble, K. L., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.141323 · Cited by 34
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Gawrieh, S., & Chalasani, N. (2015) · Seminars in Liver Disease · doi:10.1055/s-0035-1562951 · Cited by 35
Ramanjaneya, M., Bensila, M., Bettahi, I., Jerobin, J., Samra, T. A., Aye, M. M., Alkasem, M., Siveen, K. S., Sathyapalan, T., Skarulis, M. C., et al. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.568500 · Cited by 34
Plasma proteomic signature of fatty liver disease: The Rotterdam Study
Abozaid, Y. J., Ayada, I., van Kleef, L. A., Vallerga, C. L., Pan, Q., Brouwer, W. P., Ikram, M. A., van Meurs, J. B. J., de Knegt, R. J., & Ghanbari, M. (2023) · Hepatology · doi:10.1097/hep.0000000000000300 · Cited by 34
Cole, A. J., Teigen, L. M., Jahansouz, C., Earthman, C. P., & Sibley, S. D. (2015) · Current Obesity Reports · doi:10.1007/s13679-015-0171-x · Cited by 34
Recently Discovered Adipokines and Cardio-Metabolic Comorbidities in Childhood Obesity
Barraco, G. M., Luciano, R., Semeraro, M., Prieto-Hontoria, P. L., & Manco, M. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms151119760 · Cited by 33
Bisgaard, A., Sørensen, K., Johannsen, T. H., Helge, J. W., Andersson, A., & Juul, A. (2014) · International Journal of Pediatric Endocrinology · doi:10.1186/1687-9856-2014-7 · Cited by 34
Akyol, M., Alacacıoğlu, A., Demir, L., Küçükzeybek, Y., Yıldız, Y., Gumus, Z., Kara, M., Salman, T., Varol, U., Taşkaynatan, H., et al. (2017) · Cancer Biomarkers · doi:10.3233/cbm-161507 · Cited by 34
FGF21 increases water intake, urine output and blood pressure in rats
Turner, T., Chen, X., Zahner, M. R., Opsahl, A., DeMarco, G. J., Boucher, M., Goodwin, B. J., & Perreault, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202182 · Cited by 33
Bresciani, N., Demagny, H., Lemos, V., Pontanari, F., Li, X., Sun, Y., Li, H., Perino, A., Auwerx, J. H., & Schoonjans, K. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.040 · Cited by 34
Impact of Fibroblast Growth Factor 23 on Lipids and Atherosclerosis in Hemodialysis Patients
Ashikaga, E., Honda, H., Suzuki, H., Hosaka, N., Hirai, Y., Sanada, D., Nakamura, M., Nagai, H., Matsumoto, K., Kato, N., et al. (2010) · Therapeutic Apheresis and Dialysis · doi:10.1111/j.1744-9987.2009.00796.x · Cited by 34
Endogenous ways to stimulate brown adipose tissue in humans
Broeders, E. P. M., Bouvy, N. D., & Lichtenbelt, W. D. V. M. (2014) · Annals of Medicine · doi:10.3109/07853890.2013.874663 · Cited by 37
Modulation of energy balance by fibroblast growth factor 21
Ramos, D. C., & Aguilar-Salinas, C. A. (2016) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2016-0023 · Cited by 36
Early postnatal soluble FGFR3 therapy prevents the atypical development of obesity in achondroplasia
Saint-Laurent, C., García, S., Sarrazy, V., Dumas, K., Authier, F., Sore, S., Tran, A., Gual, P., Gennero, I., Salles, J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195876 · Cited by 34
Hepatic FGF21: Its Emerging Role in Inter-Organ Crosstalk and Cancers
Sui, Y., & Chen, J. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.76924 · Cited by 33
Rosenstock, M., Tseng, L., Pierce, A. A., Offman, E., Chen, C.-Y., Charlton, R., Margalit, M., & Mansbach, H. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.123.001618 · Cited by 31
Influence of intermittent fasting on autophagy in the liver
Ma, Y., Jiang, X., Tang, W., & Song, P. (2023) · BioScience Trends · doi:10.5582/bst.2023.01207 · Cited by 36
Xin, M., Bi, F., Wang, C., Huang, Y., Xu, Y., Liang, S., Cai, T., Xu, X., Dong, L., Li, T., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.04.005 · Cited by 35
Kim, J. K., Yoo, C., Cha, Y. H., & Kim, Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.09.014 · Cited by 33
Alcoholic fatty liver is enhanced in CYP2A5 knockout mice: The role of the PPARα-FGF21 axis
Chen, X., Ward, S. C., Cederbaum, A. I., Xiong, H., & Lu, Y. (2017) · Toxicology · doi:10.1016/j.tox.2017.01.016 · Cited by 33
Nguyen, A. N., Song, J.-A., Nguyen, M. T., Do, B. H., Kwon, G. G., Park, S. S., Yoo, J., Jang, J., Jin, J., Osborn, M. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-16167-x · Cited by 33
Weng, Y., Ishino, T., Sievers, A., Talukdar, S., Chabot, J., Tam, A. S. P., Duan, W., Kerns, K. M., Sousa, E. A., He, T., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22456-w · Cited by 33
Hepatic tristetraprolin promotes insulin resistance through RNA destabilization of FGF21
Sawicki, K. T., Chang, H., Shapiro, J. S., Bayeva, M., Jesus, A. D., Finck, B. N., Wertheim, J. A., Blackshear, P. J., & Ardehali, H. (2018) · JCI Insight · doi:10.1172/jci.insight.95948 · Cited by 33
Beige Fat, Adaptive Thermogenesis, and Its Regulation by Exercise and Thyroid Hormone
Phillips, K. J. (2019) · Biology · doi:10.3390/biology8030057 · Cited by 35
Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling
Agrawal, S., Maity, S., Alraawi, Z., Al-Ameer, M., & Kumar, T. K. S. (2020) · Current Drug Targets · doi:10.2174/1389450121999201012201926 · Cited by 34
En, M., Kazantseva, A. Y., Dubinina, A., Jakovleva, T., Balybina, N., Baranov, K. O., & Бажан, Н. М. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910561 · Cited by 33
Shah, N. Z., Abdalla, M. A., Deshmukh, H., & Sathyapalan, T. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211042145 · Cited by 39
Fibroblast growth factor 23--structure, function and role in kidney diseases.
Kocełak, P., Olszanecka‐Glinianowicz, M., & Chudek, J. T. (2012) · PubMed · Cited by 33
Kim, W. J., Kim, S. S., Lee, H. C., Song, S. H., Bae, M. J., Yi, Y., Jeon, Y. K., Kim, B. H., Kim, Y. K., & Kim, I. J. (2015) · Journal of Korean Medical Science · doi:10.3346/jkms.2015.30.5.586 · Cited by 33
Archer, A., Venteclef, N., Mode, A., Pedrelli, M., Gabbi, C., Clément, K., Parini, P., Gustafsson, J.-Α., & Korach-André, M. (2012) · Molecular Endocrinology · doi:10.1210/me.2012-1151 · Cited by 33
Jun, H., Joshi, Y., Patil, Y. N., Noland, R. C., & Chang, J. S. (2014) · Diabetes · doi:10.2337/db13-1837 · Cited by 33
Molecular mechanisms of fatty liver in obesity
Gan, L., Xiang, W., Xie, B., & Yu, L. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0410-2 · Cited by 37
Plasma Concentrations of Fibroblast Growth Factors 21 and 19 in Patients with Cushing's Syndrome
Ďurovcová, V., Marek, J., Hána, V., Matoulek, M., Zikán, V., Haluzíková, D., Kaválková, P., Lacinová, Z., Kršek, M., & Haluzı́k, M. (2010) · Physiological Research · doi:10.33549/physiolres.931801 · Cited by 33
Sun, L., Yan, J., Goh, H. J., Govindharajulu, P., Verma, S. K., Michael, N., Sadananthan, S. A., Henry, C. J., Velan, S. S., & Leow, M. K. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa005 · Cited by 35
Yadav, P., Khurana, A., Bhatti, J. S., Weiskirchen, R., & Navik, U. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106426 · Cited by 32
Wang, Y.-S., Ye, J., Cao, Y.-H., Zhang, R., Liu, Y., Zhang, S.-W., Dai, W., & Zhang, Q. (2019) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2018-136002 · Cited by 32
TNIK is a conserved regulator of glucose and lipid metabolism in obesity
Pham, T. C. P., Dollet, L., Ali, M. S., Raun, S. H., Møller, L. L. V., Jafari, A., Ditzel, N., Andersen, N. R., Fritzen, A. M., Gerhart‐Hines, Z., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf7119 · Cited by 33
Nicolaisen, T. S., Lyster, A. E., Sjøberg, K. A., Haas, D. T., Voldstedlund, C. T., Lundsgaard, A., Jensen, J. K., Madsen, E. M., Nielsen, C. K., Bloch‐Ibenfeldt, M., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01236-7 · Cited by 39
Lindegaard, B., Hvid, T., Grøndahl, T. S., Frøsig, C., Gerstoft, J., Højman, P., & Pedersen, B. K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055632 · Cited by 32
Bone Metabolism in Anorexia Nervosa
Fazeli, P. K., & Klibanski, A. (2014) · Current Osteoporosis Reports · doi:10.1007/s11914-013-0186-8 · Cited by 37
Wang, C., Dai, J., Yang, M., Deng, G., Xu, S., Jia, Y., Boden, G. H., Ma, Z. A., Yang, G., & Li, L. (2014) · FEBS Journal · doi:10.1111/febs.12767 · Cited by 32
Fibroblast growth factor 21 in breast milk controls neonatal intestine function
Gavaldà‐Navarro, A., Hondares, E., Giralt, M., Mampel, T., Iglesias, R., & Villarroya, F. (2015) · Scientific Reports · doi:10.1038/srep13717 · Cited by 32
Knott, M. E., & Minatta, J. N. (2016) · Journal of Molecular Biomarkers & Diagnosis · doi:10.4172/2155-9929.s2-015 · Cited by 32
Li, G.-H., Yin, J., Fu, J., Li, L., Grant, S. F. A., Li, Z., Li, M., Mi, J., Li, M., & Gao, S. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.003 · Cited by 32
Yılmaz, Ü., Tekin, S., Demir, M. T., Çiğremiş, Y., & Sandal, S. (2018) · The Journal of Physiological Sciences · doi:10.1007/s12576-018-0595-7 · Cited by 30
A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity
Shi, S. Y., Lu, Y., Liu, Z., Stevens, J. L., Murawsky, C. M., Wilson, V., Hu, Z., Richards, W. G., Michaels, M. L., Zhang, J., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.001752 · Cited by 32
A systematic dissection of sequence elements determining β-Klotho and FGF interaction and signaling
Shi, S. Y., Lu, Y., Richardson, J., Min, X., Weiszmann, J., Richards, W. G., Wang, Z., Zhang, Z., Zhang, J., & Li, Y. (2018) · Scientific Reports · doi:10.1038/s41598-018-29396-5 · Cited by 31
Yan, X., Gou, Z., Li, Y., Wang, Y., Zhu, J., Xu, G., & Zhang, Q. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-018-0846-x · Cited by 32
Holm, M. R., Christensen, H., Rasmussen, J., Johansen, M. L., Schou, M., Faber, J. O., & Kistorp, C. (2019) · ESC Heart Failure · doi:10.1002/ehf2.12502 · Cited by 32
Šimják, P., Cinkajzlová, A., Anderlová, K., Kloučková, J., Kratochvílová, H., Lacinová, Z., Kaválková, P., Krejčí, H., Mráz, M., Pařı́zek, A., et al. (2018) · Physiological Research · doi:10.33549/physiolres.934017 · Cited by 32
Kim, J. B., Lee, G. Y., Maeng, H. J., Kim, H., Bae, J. H., Kim, K. M., & Lim, S. K. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.781 · Cited by 33
Dai, Q., Fan, X., Meng, X., Sun, S., Su, Y., Ling, X., Chen, X., Wang, K., Dai, X., Zhang, C., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16369 · Cited by 33
López-Bermudo, L., Luque‐Sierra, A., Maya‐Miles, D., Gallego‐Durán, R., Ampuero, J., Romero‐Gómez, M., Berná, G., & Martı́n, F. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.892672 · Cited by 34
Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges
Tian, H., Zhang, S., Liu, Y., Wu, Y., & Zhang, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054583 · Cited by 33
A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog
Song, L., Zhu, Y., Wang, H., Belov, A. A., Niu, J., Shi, L., Xie, Y., Ye, C., Li, X., & Huang, Z. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.03.023 · Cited by 32
Liu, Y., Wang, C., Wang, Y., Ma, Z., Xiao, J., McClain, C. J., Li, X., & Feng, W. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.08.003 · Cited by 32
Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases
Cheung, B. M. Y., & Deng, H. (2014) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2014.904745 · Cited by 32
The role of bone in phosphate metabolism
Fukumoto, S. (2008) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.08.031 · Cited by 32
Xia, X., Babcock, J. P., Blaber, S. I., Harper, K. M., & Blaber, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048210 · Cited by 32
Ye, D., Li, H., Wang, Y., Jia, W., Zhou, J., Fan, J., Man, K., Lo, C., Wong, C., Wang, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep19776 · Cited by 32
Woolsey, S., Beaton, M. D., Mansell, S. E., Leon‐Ponte, M., Yu, J., Pin, C. L., Adams, P. C., Kim, R. B., & Tirona, R. G. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.104687 · Cited by 32
Liang, P., Zhong, L., Gong, L., Wang, J., Zhu, Y., Liu, W., & Yang, J. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3140 · Cited by 32
Fujii, N., Uta, S., Kobayashi, M., Sato, T., Okita, N., & Higami, Y. (2019) · Experimental Gerontology · doi:10.1016/j.exger.2019.01.001 · Cited by 32
FGF21 controls hepatic lipid metabolism via sex-dependent interorgan crosstalk
CHAFFIN, A. T. B., Larson, K. R., Huang, K.-P., Wu, C.-T., Nadejda, G., Fang, Y., Jayakrishnan, D., Sauza, K. A. S., Sims, L. C., Mohajerani, N., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.155848 · Cited by 31
Post, A., Dam, W., Sokooti, S., Groothof, D., Gloerich, J., van Gool, A. J., Kremer, D., Gansevoort, R. T., van den Born, J., Kema, I. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac729 · Cited by 30
Li, G., Chen, H.-Q., Shen, F., Smithson, S. B., Shealy, G. L., Ping, Q., Liang, Z., Han, J., Adams, A. C., Li, Y., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000433 · Cited by 30
Role of FGF19 induced FGFR4 activation in the regulation of glucose homeostasis
Wu, X., & Li, Y. (2009) · Aging · doi:10.18632/aging.100108 · Cited by 30
Sun, M. Y., Yoo, E., Green, B. J., Altamentova, S. M., Kilkenny, D. M., & Rocheleau, J. V. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.10.028 · Cited by 31
Panera, N., Corte, C. D., Crudele, A., Stronati, L., Nobili, V., & Alisi, A. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1110485 · Cited by 31
The Ablation of Mitochondrial Protein Phosphatase Pgam5 Confers Resistance Against Metabolic Stress
Sekine, S., Akari, Y., Hattori, K., Sugawara, S., Naguro, I., Koike, M., Uchiyama, Y., Takeda, K., & Ichijo, H. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.01.031 · Cited by 31
Elbelt, U., Hofmann, T., & Stengel, A. (2013) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e328363bc65 · Cited by 30
Higher serum levels of fibroblast growth factor 21 in old patients with cachexia
Franz, K., Ost, M., Otten, L., Herpich, C., Coleman, V., Endres, A., Klaus, S., Müller‐Werdan, U., & Norman, K. (2018) · Nutrition · doi:10.1016/j.nut.2018.11.004 · Cited by 31
Ji, F., Liu, Y., Hao, J., Wang, L., Dai, M.-J., Shen, G.-F., & Yan, X. (2019) · Aging · doi:10.18632/aging.102293 · Cited by 31
FGF21 Induced by the ASK1-p38 Pathway Promotes Mechanical Cell Competition by Attracting Cells
Ogawa, M., Kawarazaki, Y., Fujita, Y., Naguro, I., & Ichijo, H. (2020) · Current Biology · doi:10.1016/j.cub.2020.11.052 · Cited by 31
Plummer, J. D., Postnikoff, S. D. L., Tyler, J. K., & Johnson, J. E. (2021) · eLife · doi:10.7554/elife.62483 · Cited by 31
Fibroblast growth factor 21 and bone homeostasis
Tang, Y., & Zhang, M. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.07.002 · Cited by 31
Fibroblast growth factor 21 as a potential master regulator in metabolic disorders
Velingkar, A., Vuree, S., Prabhakar, P. K., Kalashikam, R. R., Banerjee, A., & Kondeti, S. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00244.2022 · Cited by 32
on behalf of the FIELD study investigators, Ong, K. L., Januszewski, A. S., O'Connell, R. L., Buizen, L., Jenkins, A. J., Xu, A., SULLIVAN, D. R., Barter, P. J., Scott, R. S., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3652-2 · Cited by 31
Role of fibroblast growth factors in organ regeneration and repair
Agha, E. E., Kosanovic, D., SCHERMULY, R. T., & Bellusci, S. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.10.009 · Cited by 33
Fibroblast growth factor 21 enhances cholesterol efflux in THP-1 macrophage-derived foam cells
Shang, W., Yu, X., Wang, H., CHEN, T., Fang, Y., Yang, X., Zhou, P., Nie, F., ZHOU, Q., & Zhou, J.-Z. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2731 · Cited by 32
miR‐149 controls non‐alcoholic fatty liver by targeting FGF ‐21
Xiao, J., Lv, D., Zhao, Y., Chen, X., Song, M., Liu, J., Bei, Y., Wang, F., Yang, W., & Yang, C. (2016) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12848 · Cited by 31
Tomé, D., Chaumontet, C., Even, P. C., Darcel, N., & Azzout-Marniche, D. (2019) · Physiology & Behavior · doi:10.1016/j.physbeh.2019.03.012 · Cited by 24
Metadata
- Authors
- Kharitonenkov, A., Shiyanova, T. L., Koester, A., Ford, A. M., Micanovic, R., Galbreath, E. J., Sandusky, G. E., Hammond, L. J., Moyers, J. S., Owens, R. A., Gromada, J., Brozinick, J. T., Hawkins, E. D., Wroblewski, V. J., Li, D.-S., Mehrbod, F., Jaskunas, S. R., & Shanafelt, A. B.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Kharitonenkov, Alexei
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2005-06-01
- Volume
- 115
- Issue
- 6
- Pages
- 1627-1635
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC1088017
- OpenAlex
- W2000665430
- Cited by
- 2,125
- References
- 46
- Citations by year
- 2026: 72 · 2025: 99 · 2024: 111 · 2023: 120 · 2022: 137 · 2021: 138 · 2020: 116 · 2019: 136 · 2018: 147 · 2017: 135 · 2016: 142 · 2015: 155 · 2014: 124 · 2013: 125 · 2012: 115
- FWCI
- 8.78
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Hospital for Sick Children
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fibroblast Growth Factor Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- FGF21, diabetes mellitus, glucose uptake, adipocytes, diet-induced obesity, transgenic mice, ob/ob mice, db/db mice, plasma glucose, triglycerides, metabolic regulation, diabetes treatment
- MeSH terms
- Animals, Blood Glucose, Cell Division, Cells, Cultured, Diabetes Mellitus, Fibroblast Growth Factors, Humans, Hyperglycemia, Hypoglycemic Agents, Mice, Obese, Mice, Transgenic, Triglycerides, Weight Gain, Adipocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
